Lupin share price traded under selling pressure in Wednesday's trade to quote at Rs 2,230.60 per share on the NSE, down 1.75 ...

New Delhi: Home-grown pharma major Lupin Ltd on Wednesday said it has entered into a non-exclusive patent licence agreement ...

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company leveraging its proprietary DiffuSphere technology to optimize drug delivery for applications with significant unmet need, ...

Lupin has announced a non-exclusive patent licence agreement with Takeda for the commercialisation of Vonoprazan Tablets in ...

Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug ...

Lupin announced that it has entered into a non-exclusive patent license agreement with Takeda Pharmaceutical Company (Takeda), to commercialize Vonoprazan Tablets in the Indian market.

Implantica has unveiled positive two-year results for its RefluxStop device, an implant designed to manage gastro-oesophageal ...

Doctors at the four hospitals—Ochsner Health, Tulane Medical Center, Mayo Clinic, and USC Keck—who evaluated me for a liver ...

Lupin has entered into a patent license agreement with Takeda to commercialise Vonoprazan tablets, a novel gastrointestinal ...

The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal ...

The FDA okays AstraZeneca's Fasenra for treating adults with eosinophilic granulomatosis with polyangiitis. This is the ...